Ghulam Rehman Mohyuddin
Overview
Explore the profile of Ghulam Rehman Mohyuddin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
332
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gyawali B, Eisenhauer E, van der Graaf W, Booth C, Cherny N, Goodman A, et al.
Lancet Oncol
. 2025 Feb;
26(2):e80-e89.
PMID: 39914429
Common Sense Oncology (CSO) prioritises treatments providing meaningful benefits for people with cancer. Here, we describe CSO principles aimed at improving the design, analysis, and reporting of randomised, controlled, phase...
2.
Mohyuddin G, Almasri J, Goodman A, Haslam A, Prasad V
Oncologist
. 2024 Dec;
PMID: 39719103
Introduction: Prior studies have evaluated the level of evidence behind treatment options listed in the National Comprehensive Cancer Network (NCCN) guidelines, but no study has categorized the life cycle of...
3.
Kapur R, McCarron J, Rajeeve S, Mohyuddin G
Leuk Lymphoma
. 2024 Oct;
66(2):355-357.
PMID: 39428663
No abstract available.
4.
Mohyuddin G, Mian H, Gayowsky A, Seow H, Chakraborty R, Pond G, et al.
Blood Cancer J
. 2024 Oct;
14(1):181.
PMID: 39414772
No abstract available.
5.
Vaquera-Alfaro H, Gomez-De Leon A, Desai N, Mehra N, Mohyuddin G
Bone Marrow Transplant
. 2024 Oct;
60(1):3-5.
PMID: 39370490
No abstract available.
6.
Zhukovsky S, Cliff E, Mohyuddin G
Lancet Haematol
. 2024 Oct;
11(10):e715-e717.
PMID: 39362738
No abstract available.
7.
Ebraheem M, Chakraborty R, Rochwerg B, Visram A, Mohyuddin G, Venner C, et al.
Blood Adv
. 2024 Sep;
8(23):5993-6002.
PMID: 39348665
Quadruplet regimens (anti-CD38 monoclonal antibodies [mAbs] with proteasome inhibitor [PI] and immunomodulatory drugs [IMiDs]) are increasingly being investigated in newly diagnosed multiple myeloma (NDMM). The objective of our study was...
8.
Zhukovsky S, White J, Chakraborty R, Costa L, Van Oekelen O, Sborov D, et al.
Leuk Lymphoma
. 2024 Sep;
65(14):2163-2172.
PMID: 39314111
Patients with certain subsets of multiple myeloma continue to have poor outcomes and are in need of novel treatment approaches. Strict eligibility criteria for randomized controlled trials (RCTs) limit access...
9.
Kakkilaya A, Trando A, Cliff E, Mian H, Al Hadidi S, Aziz M, et al.
Oncologist
. 2024 Sep;
30(2).
PMID: 39236068
Background: Smoldering multiple myeloma (SMM), an asymptomatic precursor of multiple myeloma (MM), carries a variable risk of progression to MM. There is little consensus on the efficacy or optimal timing...
10.
Visram A, Chan K, Seow H, Pond G, Gayowsky A, Mohyuddin G, et al.
Haematologica
. 2024 Sep;
110(1):228-233.
PMID: 39219457
No abstract available.